Dr. Lore Gruenbaum is the Chief Scientific Officer of Blood Cancer United overseeing all biomedical research activities and grants programs. Lore joined Blood Cancer United (back then The Leukemia & Lymphoma Society) in 2020 as the Vice President for the Therapy Acceleration Program (TAP), Blood Cancer United’s venture philanthropy program aiming to accelerate high-risk, innovative blood cancer therapeutics. In 2023, Lore took on oversight of the Beat AML Master Clinical trial and implemented a new strategy to expand the range of clinical trials conducted under the master protocol and reach additional patient populations.
Lore brought more than 20 years of drug discovery and clinical development experience to Blood Cancer United working on small molecules, biologics, RNA-directed and cell therapies in therapeutic areas including oncology, immunology, virology and neuroscience. Prior to joining Blood Cancer United, Lore was employed as the Vice President, Biology at Gotham Therapeutics pioneering drug discovery for novel cancer therapeutics targeting RNA regulation. She was part of the executive leadership team at Applied Biomath, a boutique consulting and mathematical modeling firm, where she led collaborative projects to accelerate and de-risk drug development for biotech and pharma and acted as the principal investigator on a NIH small business grant. Lore has helped advance more than 20 drug candidates into clinical trials and has worked on three FDA-approved drugs. Earlier in her career, she held roles at Boehringer Ingelheim and Roche Pharmaceuticals driving technical innovation, drug discovery, predictive toxicology, innovative biomarker strategies and experimental medicine studies. She completed her Ph.D. with ‘summa cum laude’ at Free University of Berlin, Germany and conducted postdoctoral studies at Yale University.